CRB0017
CRB0017 is a recombinant monoclonal antibody targeting ADAMTS5, with high affinity for the spacer domain of ADAMTS5 and strong antigen specificity. CRB0017 binds to the spacer domain of ADAMTS5 and reduces the proteolytic activity of this enzyme. CRB0017 delays articular cartilage degradation, alleviates the pathological severity of osteoarthritis, and decreases the osteoarthritis histopathological score. CRB0017 is applicable to the research of osteoarthritis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
ADAMTS5 |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:STR/ort (male, 5 months of age at study start)[1]
-
Dosage:1.2 mg per knee; 12 mg per knee
-
Administration:intra-articular; 2 doses total 6 weeks apart
-
Result:Reduced all OA histopathological scores (grade, stage, cell loss, GAG loss, OARSI score, Mankin’s score, total score) in a dose-dependent manner.
Decreased all parameters statistically significantly compared to vehicle at 12 mg per knee dose.
Showed a non-significant trend toward decreased scores for all parameters at 1.2 mg per knee dose.
Target
ADAMTS5
Anwendung
ELISA, FACS, Functional assay
Product Details
Product Properties
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)